VBL Therapeutics To Present Complete Phase 2 Data On VB-111 In Combination With Bevacizumab In Recurrent GBM At The

Press/Media: Press / Media

PeriodSep 18 2015

Media coverage

1

Media coverage

  • TitleVBL Therapeutics To Present Complete Phase 2 Data On VB-111 In Combination With Bevacizumab In Recurrent GBM At The
    Media name/outletBioSpace
    CountryUnited States
    Date9/18/15
    PersonsAndrew Brenner